Increasing competition in molecular diagnostics
New entrants from biochemistry/ELISA are entering molecular diagnostics due to high margins, pressuring pricing and market share.
3BBLACKBIODX / Q3-FY26 / risks
Keep the risk register visible.
3B Blackbio DX · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
HAT contract sunset risk
The WHO HAT contract (~$1.5M/year) will end in ~2 years; replacement revenue from US FDA is uncertain.
Slow NGS adoption and low margins
NGS segment has low margins and slow traction; management views it as a technology hedge rather than a growth driver.
Credit period extension impacting cash flow
Industry credit periods have extended to 3-5 months, matching competitors, which could pressure working capital.